Bone Marrow Transplantation News

A pivotal trial designed to assess KD025 for patients with pretreated chronic graft-versus-host disease met its primary endpoint of overall response rate, according to results from a planned interim analysis.

ASH announced the election of three clinicians to leadership positions within the society.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

A study by the NCI-sponsored SWOG Cancer Research Network showed nearly half of the network’s phase 3 clinical trials influenced clinical care guidelines or new drug approvals.

A phase 3 trial designed to evaluate ruxolitinib for steroid-refractory acute graft-versus-host disease met its primary endpoint, the agent’s manufacturer announced in a press release.

The FDA granted fast track designation to T-Guard for treatment of patients who develop steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

ASH awarded $150,000 each to 19 investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

The Seattle Cancer Care Alliance, the clinical care partner of the Fred Hutchinson Cancer Research Center, has been at the forefront of cellular therapies for cancer treatment since the field emerged. It was there where E. Donnall Thomas, MD, and his team pioneered the use of bone marrow transplant during the 1970s and SCCA’s position remains unchanged in the field of cellular therapies as its research and clinical staff have administered more CAR T-cell therapies to patients than any other facility in the world.

Detection of human herpesvirus 6B in bronchoalveolar lavage fluid appeared associated with higher risk for mortality among allogeneic hematopoietic stem cell transplant recipients with lower respiratory tract disease, according to results of a retrospective, single-center study published in Journal of Clinical Oncology.

Chronic graft-versus-host disease can be a debilitating and even life-threatening complication of allogeneic hematopoietic stem cell transplantation.